As of Q4'25, Johnson & Johnson's Operating ROA stands at 2.57%, with ROE at 6.27% and ROIC at 4.12%. These latest figures reflect a moderate improvement from the previous quarter, indicating a slight recovery in profitability metrics at the end of the observed period. From Q1'23 to Q4'25, the chart shows significant volatility across all three metrics, with notable peaks in Q3'23 (ROA at 15.67%, ROE at 36.54%, ROIC at 25.92%) followed by sharp declines. After the spike, all values trended downward and stabilized at lower levels, with minor fluctuations. This pattern suggests that while Johnson & Johnson experienced a brief period of exceptional operating efficiency in late 2023, its returns have since normalized, maintaining a relatively stable but subdued performance through 2024 and into 2025.